Browsing Tag
rare cancers
2 posts
Can ODM-212 validate TEAD inhibition as a viable oncology strategy in mesothelioma?
Can Orion Corporation’s ODM-212 prove TEAD inhibition works in mesothelioma? Discover what this FDA orphan designation really signals.
Will CABOMETYX secure EU approval for advanced neuroendocrine tumors after CHMP’s positive opinion?
Ipsen’s CABOMETYX receives EMA's CHMP backing for advanced neuroendocrine tumors; EU approval expected in 2025 following FDA nod.